.jpg "Dynavax (NASDAQ: DVAX)")
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dynavax (NASDAQ: DVAX), Mallinckrodt (NYSE: MNK) and Endo International (NASDAQ: ENDP).
Dynavax (NASDAQ: DVAX)
In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Dynavax (NASDAQ: DVAX), with a price target of $27. The company’s shares opened today at $16.60.
Piros noted:
“HEPLISAV-B Launched. Dynavax reported that HEPLISAV-B, a two-dose hepatitis B vaccine, has been launched in the U.S. with a 60-person field sales team covering 75% of the market. HEPLISAV-B was recommended by the CDC for use in the vaccination of adults, which the company believes is critical to drive broad insurance coverage and adoption. By now, 100% of Medicare lives, 74% of commercially-insured lives, and 60% of lives covered under Medicaid plans have HEPLISAV-B specific CPT codes, referencing the correct price. In the first two months following launch, the sales team met two-thirds of the targeted key accounts, corresponding to more than half of the addressable market. The sales cycle is estimated to be 6-8 weeks at this stage. As previously reported, the company has a drug supply of over 250,000 vials, with an additional 750,000 vials worth of raw material.”
According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -4.1% and a 47.6% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Dynavax has an analyst consensus of Strong Buy, with a price target consensus of $29.40.
See today’s analyst top recommended stocks >>
Mallinckrodt (NYSE: MNK)
In a report released today, Dewey Steadman from Canaccord Genuity maintained a Hold rating on Mallinckrodt (NYSE: MNK), with a price target of $14. The company’s shares opened today at $12.33, close to its 52-week low of $11.65.
According to TipRanks.com, Steadman is ranked 0 out of 5 stars with an average return of -6.5% and a 34.9% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Cardiome Pharma Corp.
Currently, the analyst consensus on Mallinckrodt is Moderate Buy and the average price target is $20.60, representing a 67.1% upside.
In a report issued on May 2, B.Riley FBR also initiated coverage with a Hold rating on the stock with a $15 price target.
Endo International (NASDAQ: ENDP)
Guggenheim analyst Rohit Vanjani maintained a Hold rating on Endo International (NASDAQ: ENDP) today. The company’s shares opened today at $5.79, close to its 52-week low of $5.27.
Vanjani noted:
“We maintain our NEUTRAL rating. 1Q18 Results: ENDP reported revenue of $700.5M, which was above the Street estimate of $691.9M but below our $727.4M forecast. Vasostrict sales of $113.7M (+15% y/y and Q/Q) helped drive the beat and benefitted from ~$10M of favorable buying patterns in the quarter. Adj. gross margin improved by 810bp y/y, due to product mix and cost improvement initiatives, which in turn led to an adj. EPS of $0.67, which was above both our/consensus estimates of $0.60/$0.55. Management reaffirmed FY2018 guidance, though revenue and adj. gross margin in 2Q is now expected to be lower than 1Q due to a reversal of the Vasostrict benefit.”
According to TipRanks.com, Vanjani is a 4-star analyst with an average return of 10.6% and a 50.4% success rate. Vanjani covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Revance Therapeutics, and Impax Laboratories.
Currently, the analyst consensus on Endo International is Hold and the average price target is $8.08, representing a 39.6% upside.
In a report issued on April 26, Cantor Fitzgerald also maintained a Hold rating on the stock with a $7 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ENDP:
